We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Hematology Analyzers Offer Channel for Immature Platelet Fraction

By LabMedica International staff writers
Posted on 18 Jul 2012
AACC 2012: A hematology analyzer includes a fluorescent platelet channel for Immature Platelet Fraction (IPF), which will aid in the differential diagnosis of thrombocytopenia. More...
The scalable, series-wide compact design delivers a smaller footprint that improves workflow and transforms productivity.

The analyzers are among products from Sysmex's hematology, urinalysis, cell image analysis, and middleware portfolio that are on show at the annual AACC/AACLS conference Expo being held July 15-19, 2012, in Los Angeles, (CA, USA).

The Sysmex (Mundelein, IL, USA) XN-Series Hematology Analyzers enable laboratories of any size to implement advanced clinical parameters. The scalable, series-wide compact design delivers a smaller footprint that optimizes workflow and transforms productivity. The instruments are built on the concept of Silent Design, a fusion of product design and technology.

Expo in-booth educational presentations will feature topics about hematology technology, diabetes management, and advanced clinical parameters, among others. Sysmex manufactures clinical laboratory solutions, including clinical diagnostics, automation, and information systems, and services hospitals and healthcare networks, reference laboratories, and physicians' offices worldwide.

The Sysmex XN-Series Hematology Analyzer has been designed to enable clinical laboratories to withstand future medical technologist shortages; and the ability to keep up with workload demands and testing complexity that may accompany an aging population. "The human-centered approach of Silent Design, upon which the Sysmex XN-Series hematology analyzers are built, provides a simplified system of operation and interface based on careful study of laboratory processes, the relationship between the operator and the instrument, and how people work," said Ralph Taylor, executive vice president, marketing, business development, and medical affairs, Sysmex America, Inc.

Related Links:

Sysmex America




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.